Prostatype Genomics AB
PGO0
Company Profile
Business description
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
Contact
Augustendalsvagen 20
Nacka Strand131 52
SWET: +46 8208700
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
6
Stocks News & Analysis
stocks
Our view after CBA shares plunge
Steady profit, but rising risks and rich valuation give pause.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Amid robust demand for semis, watch for any impact of in-house built chips and whether the supply chain is on track.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,884.70 | 18.30 | 0.21% |
| CAC 40 | 8,067.29 | 59.32 | 0.74% |
| DAX 40 | 24,409.33 | 272.52 | 1.13% |
| Dow JONES (US) | 49,963.15 | 269.95 | 0.54% |
| FTSE 100 | 10,335.62 | 10.27 | 0.10% |
| HKSE | 26,389.04 | 0.60 | 0.00% |
| NASDAQ | 26,503.76 | 101.42 | 0.38% |
| Nikkei 225 | 62,654.05 | 618.06 | -0.98% |
| NZX 50 Index | 13,025.07 | 37.99 | -0.29% |
| S&P 500 | 7,475.02 | 30.77 | 0.41% |
| S&P/ASX 200 | 8,640.70 | 26.00 | 0.30% |
| SSE Composite Index | 4,177.92 | 64.65 | -1.52% |